1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Resectable Sarcoma: new trials by email Literature Review of Resectable Sarcoma trials Research Report on Resectable Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) Doxorubicin, Ifosfamide, INCMGA00012 - Resectable Sarcoma | Phase 2 | Active not recruiting | Institut Bergonié | 66 | 2022-12-07 | 2026-10-08 |
| Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases Cisplatin, Isolated Chemotherapeutic Lung Perfusion, Metastasectomy - Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 99 | 2020-07-16 | 2026-08-21 |
Sarcoma (2) · Bone Neoplasms (1) · Colorectal Neoplasms (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Bone Diseases (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Rectal Diseases (1)
1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Doxorubicin (1) · Ifosfamide (1) · Metastasectomy (1) · Platinum (1)
Institut Bergonié (1) · Roswell Park Cancer Institute (1)
France (1) · United States (1)
Kenneth Seastedt (1)
2023 (1)